Doctor holding a vial of biologic material


About us

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We have two areas of focus: 1) a specialized biotherapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a public health solutions segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, acute radiation syndrome, and emerging and antibiotic resistant infectious disease.

Soligenix cares deeply and works tirelessly to improve the lives of patients worldwide. Our leadership and our Board of Directors have decades of experience in the biopharmaceutical industry, which includes unique expertise in developing orphan/rare disease therapies.

We are committed to transforming research into reality.

Specialized BioTherapeutics

Soligenix has specialized knowledge in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise. Soligenix is developing SGX301 as a first-in-class photo-dynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, SGX942, a novel innate defense regulator technology for the treatment of oral mucositis and SGX203, a proprietary formulations of oral beclomethasone 17, 21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn’s disease.

Public Health Solutions

Soligenix has extensive experience working in Public Health, including working with the US government with both grants and contracts, with total awards to date in excess of $50 million. Soligenix Public Health Solutions business segment includes active development programs for RiVax® , our ricin toxin vaccine candidate, OrbeShield®, our GI acute radiation syndrome therapeutic candidate and SGX943, our emerging and antibiotic resistant infectious disease therapeutic candidate. The development of the vaccine programs incorporates the use of a proprietary heat stabilization platform technology, known as ThermoVax®.  Currently, this business segment is supported with up to $24.7 million in government grant and contract funding from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the NIH.

Interested in learning more?